Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7832351 | GLAXOSMITHKLINE | Actuation indicator for a dispensing device |
Jun, 2023
(9 months ago) | |
US7832351 (Pediatric) | GLAXOSMITHKLINE | Actuation indicator for a dispensing device |
Dec, 2023
(3 months ago) | |
US7500444 | GLAXOSMITHKLINE | Actuation indicator for a dispensing device |
Feb, 2026
(1 year, 10 months from now) | |
US7500444 (Pediatric) | GLAXOSMITHKLINE | Actuation indicator for a dispensing device |
Aug, 2026
(2 years from now) |
Ventolin Hfa is owned by Glaxosmithkline.
Ventolin Hfa contains Albuterol Sulfate.
Ventolin Hfa has a total of 4 drug patents out of which 2 drug patents have expired.
Expired drug patents of Ventolin Hfa are:
Ventolin Hfa was authorised for market use on 19 April, 2001.
Ventolin Hfa is available in aerosol, metered;inhalation dosage forms.
The generics of Ventolin Hfa are possible to be released after 26 August, 2026.
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 19 April, 2001
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION